RxDoctor Payments Data

Ajit Kurup, MD

Family Medicine · Hyattsville, MDNPI 1417900051

Payments from drug & device makers

$1,964in general payments, 2019–2025

Across 64 payments — averaging $30.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$447
  • Next Science LLC$183
  • Bard Peripheral Vascular, Inc.$143
  • Integra Lifesciences Corporation$137
  • E.r. Squibb & Sons, L.L.C.$132
  • Otsuka America Pharmaceutical, Inc.$123
  • plus $799 from 17 others

What the payments were for

  • Food & beverage$1,963100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,964 in reported general payments places this provider in the 75th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$573,062
Medicare patients
579
Services billed
3,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban596$181,897
BiktarvyBictegrav/Emtricit/Tenofov Ala27$113,942
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$50,494
EntrestoSacubitril/Valsartan105$35,257
SantylCollagenase Clostridium Hist.51$33,198
JardianceEmpagliflozin78$25,677
LinzessLinaclotide29$16,703
Sevelamer Carbonate77$16,330
Atorvastatin Calcium751$13,766
ProcritEpoetin Alfa46$13,340
XareltoRivaroxaban44$12,471
JanuviaSitagliptin Phosphate39$12,320
RexultiBrexpiprazole16$11,662
XiidraLifitegrast15$11,177
MultaqDronedarone Hcl28$11,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$447$33,19851 claims
AbbVieLinzess$57$16,70329 claims
Otsuka America Pharmaceutical, Inc.Rexulti$123$11,66216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Hyattsville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →